Amundi Has $41.02 Million Stake in Roivant Sciences Ltd. $ROIV

Amundi grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 41.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,480,970 shares of the company's stock after buying an additional 437,506 shares during the quarter. Amundi owned approximately 0.21% of Roivant Sciences worth $41,023,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SBI Securities Co. Ltd. increased its stake in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $47,000. Parallel Advisors LLC lifted its position in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock worth $59,000 after acquiring an additional 2,665 shares during the period. 64.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of research analyst reports. Guggenheim increased their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, May 26th. Citigroup upped their price target on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, May 21st. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a report on Friday. TD Cowen boosted their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a "buy" rating in a report on Thursday, May 21st. Finally, Weiss Ratings downgraded Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, May 22nd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $33.59.

Roivant Sciences Stock Performance

ROIV stock opened at $33.91 on Monday. The company's 50-day simple moving average is $32.63 and its 200 day simple moving average is $29.10. Roivant Sciences Ltd. has a 52 week low of $10.90 and a 52 week high of $37.00. The company has a market capitalization of $24.39 billion, a PE ratio of -56.52 and a beta of 1.12.

Insiders Place Their Bets

In other news, Director Daniel Allen Gold sold 12,380 shares of the firm's stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total transaction of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares of the company's stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company's stock, valued at approximately $56,376,551.85. The trade was a 11.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,055,913 shares of company stock worth $69,639,633 in the last quarter. 8.80% of the stock is currently owned by corporate insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.